U.S. waives tariffs on certain speciality drugs from 20 countries, including India
The U.S. government has waived tariffs on specific specialty drugs and ingredients imported from India and 19 other countries. This move follows a broader proclamation by President Trump to impose 100% tariffs on certain patented pharmaceuticals to encourage domestic production.
Why it matters
This policy shift impacts global pharmaceutical supply chains and the cost of rare disease treatments for U.S. patients.
The U.S. will not charge any ad valorem tariff on certain speciality drugs and associated ingredients used for treatment of rare medical conditions imported from India and 19 other countries.
An ad valorem tariff is a set percentage of the monetary value of the goods to be taxed, according to the World Customs Organisation.
The U.S. Commerce Department published the list of countries in the Federal Register as it prepares to impose a 100% tariff on certain patented pharmaceutical imports and their associated ingredients from September 29.
On April 2, President Donald Trump issued a proclamation to impose tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S. as part of efforts to encourage domestic production.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in